Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise
Kyverna Therapeutics (Nasdaq: KYTX) announced a virtual Key Opinion Leader (KOL) event scheduled for August 28, 2025, from 11:00am to 1:30pm ET. The event will focus on the company's neuroimmunology CAR T franchise, featuring presentations from distinguished medical experts and management team members.
The webcast will highlight KYV-101's potential in treating myasthenia gravis (MG) and stiff person syndrome (SPS), including the Phase 3 registrational trial in MG. Key topics will cover treatment landscapes, patient experiences, unmet needs, and the company's commercial strategy. The event will conclude with a Q&A session and will be accessible through the company's investor relations website.
Kyverna Therapeutics (Nasdaq: KYTX) ha annunciato un evento virtuale con Key Opinion Leader (KOL) previsto per il 28 agosto 2025, dalle 11:00 alle 13:30 ET. L'evento sarà incentrato sulla linea di prodotti CAR T neuroimmunologici dell'azienda, con presentazioni di rinomati esperti medici e membri del team di gestione.
La trasmissione in webcast metterà in evidenza il potenziale di KYV-101 nel trattamento della miastenia grave (MG) e della sindrome della persona rigida (SPS), incluso lo studio registrativo di Fase 3 per la MG. I temi principali riguarderanno i panorami terapeutici, le esperienze dei pazienti, i bisogni non soddisfatti e la strategia commerciale dell'azienda. L'evento si concluderà con una sessione di domande e risposte e sarà accessibile tramite il sito web delle relazioni con gli investitori dell'azienda.
Kyverna Therapeutics (Nasdaq: KYTX) anunció un evento virtual con Líderes de Opinión Clave (KOL) programado para el 28 de agosto de 2025, de 11:00 a.m. a 1:30 p.m. ET. El evento se centrará en la franquicia CAR T neuroinmunológica de la compañía, con presentaciones de destacados expertos médicos y miembros del equipo directivo.
La transmisión en línea destacará el potencial de KYV-101 para tratar la miastenia gravis (MG) y el síndrome de la persona rígida (SPS), incluyendo el ensayo registracional de Fase 3 en MG. Los temas clave cubrirán los panoramas de tratamiento, experiencias de los pacientes, necesidades no cubiertas y la estrategia comercial de la empresa. El evento concluirá con una sesión de preguntas y respuestas y será accesible a través del sitio web de relaciones con inversores de la compañía.
Kyverna Therapeutics (나스닥: KYTX)는 2025년 8월 28일 오전 11시부터 오후 1시 30분(동부시간)에 가상 주요 의견 리더(KOL) 행사를 개최한다고 발표했습니다. 이번 행사는 회사의 신경면역학 CAR T 프랜차이즈를 중심으로 저명한 의료 전문가 및 경영진의 발표가 진행됩니다.
웨비스트는 근무력증(MG) 및 강직성 인격 증후군(SPS) 치료에 대한 KYV-101의 잠재력을 강조하며, MG 대상 3상 등록 시험도 포함됩니다. 주요 주제로는 치료 환경, 환자 경험, 미충족 수요 및 회사의 상업 전략이 다뤄질 예정입니다. 행사는 질의응답 세션으로 마무리되며 회사 투자자 관계 웹사이트를 통해 접속할 수 있습니다.
Kyverna Therapeutics (Nasdaq : KYTX) a annoncé un événement virtuel avec des leaders d'opinion clés (KOL) prévu pour le 28 août 2025, de 11h00 à 13h30 ET. L'événement portera sur la franchise CAR T neuro-immunologique de la société, avec des présentations d'experts médicaux renommés et des membres de l'équipe de direction.
La diffusion en webcast mettra en lumière le potentiel de KYV-101 dans le traitement de la myasthénie grave (MG) et du syndrome de la personne raide (SPS), incluant l'essai d'enregistrement de phase 3 en MG. Les sujets clés aborderont les paysages thérapeutiques, les expériences des patients, les besoins non satisfaits et la stratégie commerciale de la société. L'événement se terminera par une session de questions-réponses et sera accessible via le site web des relations investisseurs de la société.
Kyverna Therapeutics (Nasdaq: KYTX) kündigte eine virtuelle Key Opinion Leader (KOL) Veranstaltung an, die für den 28. August 2025 von 11:00 bis 13:30 Uhr ET geplant ist. Die Veranstaltung konzentriert sich auf die neuroimmunologische CAR-T-Franchise des Unternehmens und beinhaltet Präsentationen von renommierten medizinischen Experten und Mitgliedern des Managementteams.
Der Webcast wird das Potenzial von KYV-101 zur Behandlung von Myasthenia gravis (MG) und Stiff-Person-Syndrom (SPS) hervorheben, einschließlich der Phase-3-Zulassungsstudie bei MG. Wichtige Themen sind Behandlungslandschaften, Patientenerfahrungen, ungedeckte Bedürfnisse und die kommerzielle Strategie des Unternehmens. Die Veranstaltung endet mit einer Fragerunde und ist über die Investor-Relations-Website des Unternehmens zugänglich.
- None.
- None.
Webcast to be held August 28, 2025, 11:00am ET
Presentations will feature members of the Company's management team and the following renowned KOLs:
- Srikanth Muppidi, M.D., Stanford Medicine
- Ricardo Grieshaber-Bouyer, M.D., Ph.D., FAU Erlangen-Nümberg
- Aiden Haghikia, M.D., Hannover Medical School (MHH)
The event will provide a deep dive into Kyverna's neuroimmunology franchise strategy, with a focus on KYV-101 and its potential in myasthenia gravis (MG) and stiff person syndrome (SPS), highlighting:
- The treatment landscape, patient experience and unmet need in MG and SPS
- KYV-101's differentiation and potential for durable drug-free, disease-free remission
- The details of our Phase 3 registrational trial in MG
- A high-level overview of Kyverna's focused commercial strategy, leading with neuroimmunology CAR T
- Multiple near-term value-creating milestones across the pipeline
Following formal presentations, management will host a Q&A session.
The event will be webcast live and those who intend to join can pre-register for the webcast here.
The live webcast and supporting presentation materials will be available on the "Events & Presentations" section of Kyverna's Investor Relations webpage at ir.kyvernatx.com. An archived replay will also be available.
About Kyverna Therapeutics
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a clinical-stage biopharmaceutical company focused on liberating patients through the curative potential of cell therapy. Kyverna's lead CAR T-cell therapy candidate, KYV-101, is advancing through late-stage clinical development with registrational trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase 1/2 trials for patients with lupus nephritis. The Company is also harnessing other KYSA trials and investigator-initiated trials, including in multiple sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Additionally, its pipeline includes next-generation CAR T-cell therapies in both autologous and allogeneic formats, including efficiently expanding into broader autoimmune indications and the potential to increase patient reach with KYV-102 using its proprietary whole blood rapid manufacturing process. For more information, please visit https://kyvernatx.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." The words, without limitation, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Forward-looking statements in this press release include, without limitation, those related to: Kyverna's upcoming virtual KOL event and the topics expected to be discussed at such event; the potential for KYV-101 to provide durable drug free, disease-free remission; Kyverna's commercial strategy and near-term value-creating milestones; the potential for KYV-102 to increase patient reach; and Kyverna's clinical trials, investigator initiated trials and named-patient activities. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to market conditions, the possibility that the FDA or other regulatory agencies may require additional trials or studies to support its intended BLA submission; intellectual property rights; and other factors discussed in the "Risk Factors" section of Kyverna's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that Kyverna has filed or may subsequently file with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release are based on the current expectations of Kyverna's management team and speak only as of the date hereof, and Kyverna specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
Investors: InvestorRelations@kyvernatx.com
Media: media@kyvernatx.com
View original content:https://www.prnewswire.com/news-releases/kyverna-therapeutics-to-host-virtual-kol-event-to-highlight-neuroimmunology-car-t-franchise-302515530.html
SOURCE Kyverna Therapeutics
FAQ
When is Kyverna Therapeutics (KYTX) hosting its KOL event and how can investors attend?
What will be discussed at the Kyverna Therapeutics (KYTX) KOL event?
Who are the Key Opinion Leaders presenting at the Kyverna (KYTX) event?
What is KYV-101 and what conditions is it targeting?
